Clopidogrel (Plavix), a P2Y 12 receptor antagonist, inhibits bone cell function in vitro and decreases trabecular bone in vivo

Journal of Bone and Mineral Research

Volumn 27, Issue 11, 2012, Pages 2373-2386

  Syberg, Susanne ^a   Brandao Burch, Andrea ^b   Patel, Jessal J ^b   Hajjawi, Mark ^b   Arnett, Timothy R ^b   Schwarz, Peter ^a   Jorgensen, Niklas R ^a   Orriss, Isabel R ^b  

^a Mental Health Center Glostrup   (Denmark)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

CLOPIDOGREL; OSTEOBLAST; P2Y 12 RECEPTOR

Indexed keywords

ALKALINE PHOSPHATASE; AMELOBLASTIN; CARBOXY TERMINAL TELOPEPTIDE; CLOPIDOGREL; COLLAGEN TYPE 1; COLLAGEN TYPE 10; OSTEOCALCIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHODIESTERASE I; PURINERGIC P2Y12 RECEPTOR; SMAD4 PROTEIN; TRANSCRIPTION FACTOR RUNX2; VASCULOTROPIN A; AZO COMPOUND; BIOLOGICAL MARKER; COLLAGEN; CYCLIC AMP; DRUG DERIVATIVE; OIL RED O; P2RY12 PROTEIN, MOUSE; PURINERGIC P2Y RECEPTOR ANTAGONIST; TICLOPIDINE;

ADIPOCYTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BONE CELL; BONE DENSITY; BONE MASS; BONE MINERAL; CELL COUNT; CELL DIFFERENTIATION; CELL FUNCTION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; COLLAGEN SYNTHESIS; CONTROLLED STUDY; CORTICAL BONE; DUAL ENERGY X RAY ABSORPTIOMETRY; FAT CONTENT; FEMALE; FEMUR; GENE EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; LONG TERM EXPOSURE; LUMBAR VERTEBRA; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; OVARIECTOMY; PROTEIN EXPRESSION; TIBIA; TRABECULAR BONE; ANIMAL; BLOOD; BONE; BONE DEVELOPMENT; CELL CULTURE; DRUG EFFECT; GENE EXPRESSION REGULATION; INTRACELLULAR SPACE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; RADIOGRAPHY; SOLUBILITY; STAINING;

ALKALINE PHOSPHATASE; ANIMALS; AZO COMPOUNDS; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; BONE RESORPTION; CELL COUNT; CELL SURVIVAL; CELLS, CULTURED; COLLAGEN; CYCLIC AMP; GENE EXPRESSION REGULATION; INTRACELLULAR SPACE; MICE; OSTEOBLASTS; OSTEOCLASTS; OSTEOGENESIS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y12; SOLUBILITY; STAINING AND LABELING; TICLOPIDINE;

EID: 84867566463     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.1690     Document Type: Article

References (54)

1. Burnstock G, Knight GE., Cellular distribution and functions of P2 receptor subtypes in different systems. Int Rev Cytol. 2004; 240: 31-04.
2. Kennedy C, Burnstock G., Evidence for two types of P2-purinoceptor in longitudinal muscle of the rabbit portal vein. Eur J Pharmacol. 1985; 111: 49-56. (Pubitemid 15097840)
3. Abbracchio MP, Burnstock G., Purinoceptors: are there families of P2X and P2Y purinoceptors?. Pharmacol Ther. 1994; 64: 445-75. (Pubitemid 24381231)
4. Ralevic V, Burnstock G., Receptors for purines and pyrimidines. Pharmacol Rev. 1998; 50: 413-92. (Pubitemid 28477681)
5. Burnstock G., Purine and pyrimidine receptors. Cell Mol Life Sci. 2007; 64: 1471-83. (Pubitemid 46954150)
6. 7 receptors in bone. Purinergic Signal. 2009; 5: 205-21.
7. Orriss IR, Burnstock G, Arnett TR., Purinergic signalling and bone remodelling. Curr Opin Pharmacol. 2010; 10: 322-30.
8. Kumagai H, Sacktor B, Filburn CR., Purinergic regulation of cytosolic calcium and phosphoinositide metabolism in rat osteoblast-like osteosarcoma cells. J Bone Miner Res. 1991; 6: 697-708.
9. Bowler WB, Birch MA, Gallagher JA, Bilbe G., Identification and cloning of human P2U purinoceptor present in osteoclastoma, bone, and osteoblasts. J Bone Miner Res. 1995; 10: 1137-45.
10. Dixon CJ, Bowler WB, Walsh CA, Gallagher JA., Effects of extracellular nucleotides on single cells and populations of human osteoblasts: contribution of cell heterogeneity to relative potencies. Br J Pharmacol. 1997; 120: 777-80. (Pubitemid 27122715)
11. 6 cDNAs and identification of a pseudogene: comparison of P2Y receptor subtype expression in bone and brain tissues. Biochem Biophys Res Commun. 1997; 240: 298-302.
12. Hoebertz A, Townsend-Nicholson A, Glass R, Burnstock G, Arnett TR., Expression of P2 receptors in bone and cultured bone cells. Bone. 2000; 27: 503-10.
13. Orriss IR, Knight GE, Ranasinghe S, Burnstock G, Arnett TR., Osteoblast responses to nucleotides increase during differentiation. Bone. 2006; 39: 300-9. (Pubitemid 43851382)
14. Alqallaf SM, Evans BA, Kidd EJ., Atypical P2X receptor pharmacology in two human osteoblast-like cell lines. Br J Pharmacol. 2009; 156: 1124-35.
15. Nakamura E, Uezono Y, Narusawa K, Shibuya I, Oishi Y, Tanaka M, Yanagihara N, Nakamura T, Izumi F., ATP activates DNA synthesis by acting on P2X receptors in human osteoblast-like MG-63 cells. Am J Physiol Cell Physiol. 2000; 279: C510-9.
16. 2+]i release in rat osteoblasts independently of Gq activation or cyclic monophosphate accumulation. A mechanism for localizing systemic responses in bone. J Biol Chem. 2001; 276: 9565-71.
17. Bowler WB, Buckley KA, Gartland A, Hipskind RA, Bilbe G, Gallagher JA., Extracellular nucleotide signalling: a mechanism for integrating local and systemic responses in the activation of bone remodeling. Bone. 2001; 28: 507-12. (Pubitemid 32410002)
18. Ihara H, Hirukawa K, Goto S., Togari., ATP-stimulated interleukin-6 synthesis through P2Y receptors on human osteoblasts. Biochem Biophys Res Commun. 2005; 326: 329-34. (Pubitemid 39593550)
19. 7 nucleotide receptors mediate blebbing in osteoblasts through a pathway involving lysophosphatidic acid. J Biol Chem. 2007; 282: 3403-12. (Pubitemid 47084361)
20. 7 receptors on osteoblasts couple to production of lysophosphatidic acid: a signaling axis promoting osteogenesis. J Cell Biol. 2008; 181: 859-71. (Pubitemid 351786989)
21. 2 receptor in bone remodeling. J Cell Biochem. 2002; 86: 413-9. (Pubitemid 36076158)
22. 2 receptors and pyrophosphate. Endocrinology. 2007; 148: 4208-16. (Pubitemid 47295696)
23. 4 purinoceptors mediate an ATP-activated, non-selective cation current in rabbit osteoclasts. J Cell Sci. 1999; 112 (Pt 23): 4425-35. (Pubitemid 30122034)
24. Buckley KA, Hipskind RA, Gartland A, Bowler WB, Gallagher JA., Adenosine triphosphate stimulates human osteoclast activity via upregulation of osteoblast-expressed receptor activator of nuclear factor-kappa B ligand. Bone. 2002; 31: 582-90. (Pubitemid 35449700)
25. 7 nucleotide receptor reveals its regulatory roles in bone formation and resorption. Mol Endocrinol. 2003; 17: 1356-67. (Pubitemid 36819956)
26. 7 activation. Crit Rev Eukaryot Gene Expr. 2003; 13: 237-42. (Pubitemid 38009172)
27. 6 nucleotide receptors activate NF-{kappa}B and increase survival of osteoclasts. J Biol Chem. 2005; 280: 16909-15. (Pubitemid 41389150)
28. 6 receptor stimulates bone resorption by osteoclasts. Endocrinology. 2011; 152: 3706-16.
29. 1 receptor on bone cells. FASEB J. 2001; 15: 1139-48. (Pubitemid 32436299)
30. 7 receptor inhibits formation of multinucleated human osteoclasts in vitro. Calcif Tissue Int. 2003; 73: 361-9. (Pubitemid 37409423)
31. P2X7 receptor KN-62 antagonist are potent inducers of apoptosis of human primary osteoclasts. J Biomed Sci. 2005; 12: 1013-20. (Pubitemid 43081680)
32. 7 receptors to activate NF-kappaB in osteoclasts. J Bone Miner Res. 2004; 19: 642-51. (Pubitemid 41071225)
33. 7 receptors causes isoform-specific translocation of protein kinase C in osteoclasts. J Cell Sci. 2009; 122: 136-44.
34. 7 receptors. J Biol Chem. 2002; 277: 7574-80. (Pubitemid 34953156)
35. Wang L, Ostberg O, Wihlborg AK, Brogren H, Jern S, Erlinge D., Quantification of ADP and ATP receptor expression in human platelets. J Thromb Haemost. 2003; 1: 330-6.
36. 12 in microglia in rat brain. Glia. 2003; 44: 242-50. (Pubitemid 37484475)
37. Kim CH, Kim SS, Choi JY, Shin JH, Kim JY, Namkung W, Lee JG, Lee MG, Yoon JH., Membrane-specific expression of functional purinergic receptors in normal human nasal epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2004; 287: L835-42. (Pubitemid 39249396)
38. Jin J, Kunapuli SP., Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation. Proc Natl Acad Sci U S A. 1998; 95: 8070-4. (Pubitemid 28326067)
39. 12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries. J Clin Invest. 2003; 112: 398-406. (Pubitemid 38063768)
40. Nurden P, Savi P, Heilmann E, Bihour C, Herbert JM, Maffrand JP, Nurden A., An inherited bleeding disorder linked to a defective interaction between ADP and its receptor on platelets. Its influence on glycoprotein IIb-IIIa complex function. J Clin Invest. 1995; 95: 1612-22.
41. Savi P, Herbert JM, Pflieger AM, Dol F, Delebassee D, Combalbert J, Defreyn G, Maffrand JP., Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel. Biochem Pharmacol. 1992; 44: 527-32.
42. Pereillo JM, Maftouh M, Andrieu A, Uzabiaga MF, Fedeli O, Savi P, Pascal M, Herbert JM, Maffrand JP, Picard C., Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos. 2002; 30: 1288-95. (Pubitemid 35265838)
43. Ksycinska H, Rudzki P, Bukowska-Kiliszek M., Determination of clopidogrel metabolite (SR 26334) in human plasma by LC-MS. J Pharm Biomed Anal. 2006; 41: 533-9.
44. Weber AA, Reimann S, Schror K., Specific inhibition of ADP-induced platelet aggregation by clopidogrel in vitro. Br J Pharmacol. 1999; 126: 415-20. (Pubitemid 29057591)
45. Savi P, Pereillo JM, Uzabiaga MF, Combalbert J, Picard C, Maffrand JP, Pascal M, Herbert JM., Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost. 2000; 84: 891-6.
46. Brandao-Burch A, Utting JC, Orriss IR, Arnett TR., Acidosis inhibits bone formation by osteoblasts in vitro by preventing mineralization. Calcif Tissue Int. 2005; 77: 167-74. (Pubitemid 41569747)
47. Arnett TR, Dempster DW., Effect of pH on bone resorption by rat osteoclasts in vitro. Endocrinology. 1986; 119: 119-24. (Pubitemid 16100716)
48. Arnett TR, Gibbons DC, Utting JC, Orriss IR, Hoebertz A, Rosendaal M, Meghji S., Hypoxia is a major stimulator of osteoclast formation and bone resorption. J Cell Physiol. 2003; 196: 2-8. (Pubitemid 36676438)
49. Hoebertz A, Arnett TR., Isolated osteoclast cultures. Methods Mol Med. 2003; 80: 53-64.
50. Razzell WE, Khorana HG., Studies on polynucleotides. III. Enzymic degradation; substrate specificity and properties of snake venom phosphodiesterase. J Biol Chem. 1959; 234: 2105-13.
51. Ramirez-Zacarias JL, Castro-Munozledo F, Kuri-Harcuch W., Quantitation of adipose conversion and triglycerides by staining intracytoplasmic lipids with Oil red O. Histochemistry. 1992; 97: 493-7.
52. Martin KA, Kertesy SB, Dubyak GR., Down-regulation of P2U-purinergic nucleotide receptor messenger RNA expression during in vitro differentiation of human myeloid leukocytes by phorbol esters or inflammatory activators. Mol Pharmacol. 1997; 51: 97-108. (Pubitemid 27049550)
53. Chemnitz J, Sohngen D, Schulz A, Diehl V, Scheid C., Fatal toxic bone marrow failure associated with clopidogrel. Eur J Haematol. 2003; 71: 473-4. (Pubitemid 37467885)
54. Jørgensen NR, Grove EL, Schwarz P, Vestergaard P., Clopidogrel and risk of osteoporotic fractures: a nationwide cohort study. J Int Med. Epub. 2012 Mar 30. DOI: 10.1111/j.1365-2796.2012.02535.x.